Reuters logo
BRIEF-Pluristem completes patient enrollment in phase II trial in intermittent claudication
January 12, 2017 / 11:23 AM / 8 months ago

BRIEF-Pluristem completes patient enrollment in phase II trial in intermittent claudication

Jan 12 (Reuters) - Pluristem Therapeutics Inc

* Pluristem completes patient enrollment in a large multinational phase II trial in intermittent claudication

* Expect to report top line results in early 2018 for phase II IC trial

* Pluristem’s IC trial is evaluating safety and efficacy of PLX-PAD cells as compared to placebo Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below